Cancer Immunotherapy Co. Nabs $62M To Advance Research
Oncology treatment developer Pionyr Immunotherapeutics Inc. said Wednesday its latest funding round brought in $62 million, which will be used toward the advancement of antibody therapeutics that help the body fight...To view the full article, register now.
Already a subscriber? Click here to view full article